




December 14, 2020

Dear Fellow Stockholders,

2020 will be remembered for the COVID-19 pandemic and the many hardships it has brought to the world, but also for the countless examples of individuals and organizations that rose to the occasion to solve the myriad challenges wrought by this crisis. I am proud to say that despite the impact each of us has felt at varying levels, fiscal 2020 was one of the strongest years in the Company's 40-year history and we are proud to be playing a meaningful role in overcoming the crisis. Early in the pandemic, we were deemed an essential business because of our role in support of a cure for COVID-19 in our life sciences business, and for what we do to help sustain the remotely connected economy with our semiconductor products. Our employees at Brooks persevered through personal and professional challenges to meet the obligations of this responsibility. Since March, we have operated with the safety of our employees, customers, and suppliers as our first priority. Our teams have adhered to our safety protocols to protect one another, and in doing so, have not only kept our business running, but also lifted our two businesses to new heights. We are grateful to them for their diligence and duty that was responsible for our very strong 2020 performance.



### 2020 Recap

In the year, revenue grew 15%, with double-digit contributions from both Life Sciences and Semiconductor Solutions segments, yielding more than 200 basis points in expansion of non-GAAP operating margin and 65% growth in non-GAAP EPS - an exceptional result given the challenging environment. I am pleased to say that our journey to expand our Life Sciences business while maintaining our leadership position in Semiconductor manufacturing is progressing, and we still have many more opportunities ahead.

### Life Sciences

In our Life Sciences business, we are pleased with both our growth and the level of stability that we have achieved. We reported 16% revenue growth in 2020 and in our fourth quarter we delivered 16% non-GAAP operating margins, a 900 basis point expansion from the same quarter last year. At mid-year, we realigned our Life Sciences business into two reportable segments, Life Sciences Products and Life Sciences Services, with the objective to promote efficiency and drive more consistent growth. Our Life Sciences Services business, now led by Dr. Amy Liao, is already seeing the benefits of leveraging the more than 7,000 Brooks Life Sciences customer relationships across GENEWIZ and Sample Repository Solutions, which has helped us to win several new customer contracts. Our Life Sciences Products business, led by Robin Vacha, firmly established our position as a leading supplier of consumables and instruments, which was accelerated by the demand for automation for high volume COVID-19 testing, while further growing our position as a leader in ultra-cold sample storage systems.

As we finished the year, we achieved an important milestone in our Life Sciences business when we crossed over the \$100 million revenue threshold in Q4, putting us confidently on track for continued growth in 2021. After some market turbulence in the spring when academic lab activity slowed considerably, our GENEWIZ business rebounded to report strong growth as we exited 2020 with a recovery in Next Generation Sequencing

and Sanger Sequencing, and continued record performance from Synthesis. And, whereas GENEWIZ has been a key contributor to COVID-19 research and vaccine development, our world class Sample and Repository Solutions platform is set to bring benefits because of our important link in this critical cold vaccine supply chain. As an example, we are proud to have been selected by Catalent Biologics as a trusted partner for the storage and transport of one of their significant COVID-19 vaccine programs. We have also entered into agreements with other companies in the U.S. and Europe to support their vaccine preservation and distribution pipelines.

### **Semiconductor Solutions**

This year has also been a robust year the semiconductor capital equipment market and our Semiconductor Solutions business once again outperformed. Led by David Jarzynka, in fiscal 2020 our Semiconductor business grew 14% and delivered expanded margins across all product lines. This is especially true in vacuum automation products where our ability to outpace the market comes from a combination of secular drivers: chip technology requiring more process steps that are performed under vacuum conditions; market share gains with OEMs looking to replace their robots with our technology; and the expanding Asian OEM market where we are winning high market share. We see this trend continuing into 2021 and beyond.

In addition, our Contamination Control Solutions, or CCS, business achieved new highs during the fiscal year, growing 33% from 2019, driven by demand for our automated wafer carrier cleaning systems and reticle stockers. We plan to build on our market leading position by continuing to develop new CCS products and technologies for future device generations. We are confident we have an expanding market opportunity in front of us which includes a rapidly growing need for advanced systems to satisfy the demanding new application for extreme ultraviolet (EUV) lithography technology.

All in, we are bullish about the future of our semiconductor business. In fiscal 2020, we had a record year for design-in wins at 144, which came from 55 different OEMs and 32 end users. This was up 15% from our record in 2019. This increase is a testament to the value that we are bringing to customers and the strength of our position in these markets. We are poised for another meaningful growth year in 2021 and positioned exactly where we ought to be to once again outgrow the wafer fab equipment market.

### **Looking Forward**

In both our Life Sciences and Semiconductor businesses, we have established clear leadership positions in markets that will provide fuel for many years to come. We enter 2021 with much the same energy and momentum that we felt at this time in each of the past 3 years. Our markets are robust. Our business model is solid, and our employees are energized by, and enthusiastic about, all the potential that lies in front of us. Our outlook for 2021 is for continued growth, additional share capture, more expanded value propositions, and another step in margin expansion. We have built a foundation for high growth and accelerated profitability, and we plan to deliver.

On behalf of our Board of Directors and the entire global Brooks team, we thank our stockholders for their continued support and confidence, and we look forward to continued success in 2021.

Sincerely,



Steve Schwartz  
President and Chief Executive Officer